News | April 15, 2025
Biocon Biologics secures market entry date for Yesafili in US
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
The company does not expect this development to have any material impact on the current business operations
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
The company has entered into above Memo to settle, compromise and finally and forever resolve all disputes
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Subscribe To Our Newsletter & Stay Updated
